Premium
Albumin batches and B19 parvovirus DNA
Author(s) -
Lefrère J. J.,
Mariotti M.,
Croix I.,
Lerable J.,
Thauvin M.,
Burnouf T.,
Folléa G.
Publication year - 1995
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1995.35595259148.x
Subject(s) - parvovirus , albumin , polymerase chain reaction , population , dna , chemistry , virus , chromatography , virology , medicine , biochemistry , environmental health , gene
BACKGROUND: B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined. STUDY DESIGN AND METHODS: The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4‐ and 20‐percent albumin, respectively, from two different manufacturers. RESULTS: No B19 DNA was detected in the batches tested. CONCLUSION: The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19.